Market Overview

UPDATE: Goldman Sachs Raises PT to $170 on Regeneron Pharmaceuticals on Eylea EU Approval

Share:
Related REGN
The 5 Biggest Biotech Stocks
Notes From The Street: 'FLASHBACK....Oil Going To $200/Barrel'
Making Money With Charles Payne: 12/22/14 (Fox Business)

Goldman Sachs reiterated its Buy rating on Regeneron Pharmaceuticals (NASDAQ: REGN) and increased its price target from $168 to $170.

Goldman Sachs noted, "FDA approved REGN's Eylea for a new eye disease indication (central retinal vein occlusion, CRVO), in line with our expectation. Eylea was approved last year for the wet AMD indication. We model 2013 US Eylea sales of $1.2bn (62% yoy growth) of which CRVO contributes $104mn."

Regeneron Pharmaceuticals closed at $145.09 on Friday.

Latest Ratings for REGN

DateFirmActionFromTo
Jan 2015CitigroupMaintainsBuy
Jan 2015BarclaysInitiates Coverage onEqual-weight
Jan 2015Morgan StanleyUpgradesEqualweightOverweight

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (REGN)

Around the Web, We're Loving...

Get Benzinga's Newsletters